UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 30, 2010 (August 30, 2010)
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
| Florida
|
|
001-33357
|
|
65-0643773 |
| (State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer |
| of incorporation)
|
|
|
|
Identification No.) |
| |
|
|
|
| 2 Snunit Street |
|
|
| Science Park, POB 455 |
|
|
| Carmiel, Israel
|
|
20100 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
On August 30, 2010, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing that the Tel Aviv Stock Exchange (“TASE”) approved the dual listing of the Company’s
common stock on the TASE. Trading of the Company’s common stock on the TASE will commence on
Monday, September 6, 2010. The Company also announced today that, based upon the Company’s current
market capitalization, it expects its common stock to be included in the TA-75, TA-100, Tel-Tech,
Tel-Tech 15 and Biomed indexes beginning October 10, 2010. The Company’s common stock will
continue to be listed on the NYSE Amex, and the Company will continue to be subject to the rules
and regulations of the NYSE Amex and the U.S. Securities and Exchange Commission. A copy of the
press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
| 99.1 |
|
Press release dated August 30, 2010. |
2